Kezar Life Sciences Inc (KZR)
0.7633
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
0.7633
0.00 (0.00%)
After-Hours: 20:00
Kezar Life Sciences Research and Development Expense (Quarterly): 17.17M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 17.17M |
| December 31, 2023 | 22.64M |
| September 30, 2023 | 23.74M |
| June 30, 2023 | 21.00M |
| March 31, 2023 | 18.32M |
| December 31, 2022 | 14.86M |
| September 30, 2022 | 13.86M |
| June 30, 2022 | 11.35M |
| March 31, 2022 | 10.94M |
| December 31, 2021 | 9.781M |
| September 30, 2021 | 10.53M |
| June 30, 2021 | 9.341M |
| March 31, 2021 | 9.286M |
| December 31, 2020 | 8.117M |
| September 30, 2020 | 8.259M |
| Date | Value |
|---|---|
| June 30, 2020 | 7.148M |
| March 31, 2020 | 7.457M |
| December 31, 2019 | 7.431M |
| September 30, 2019 | 7.08M |
| June 30, 2019 | 6.925M |
| March 31, 2019 | 5.927M |
| December 31, 2018 | 4.673M |
| September 30, 2018 | 4.664M |
| June 30, 2018 | 5.228M |
| March 31, 2018 | 3.572M |
| December 31, 2017 | 1.636M |
| September 30, 2017 | 1.557M |
| June 30, 2017 | 1.445M |
| March 31, 2017 | 1.831M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.925M
Minimum
Jun 2019
23.74M
Maximum
Sep 2023
12.26M
Average
10.15M
Median
Research and Development Expense (Quarterly) Benchmarks
| Accuray Inc | 10.91M |
| Tonix Pharmaceuticals Holding Corp | 12.86M |
| Acumen Pharmaceuticals Inc | 12.45M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |